Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.78 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 2/20 | 0.67 |
| ▸ | MMP9 | P14780 | 2/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.64 |
| ▸ | ITGAV | P06756 | 1/20 | 0.64 |
| ▸ | CPB1 | P15086 | 1/20 | 0.64 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.64 |
| ▸ | TGM2 | P21980 | 3/20 | 0.64 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561005 | 1.00 | FOLH1 (0.78) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL806151 | 1.00 | FOLH1 (0.78) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL11875673 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL4173693 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL4173691 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL18907025 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157463 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL18907028 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157482 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157462 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801489-B2 | Media for separating small molecules from biomacromolecules in aqueous mixtures | KREBS JOSEPH F (US) | 2023-10-31 | — | — | US | claimed |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | MIHKAL GMBH (CH) | 2023-10-12 | — | — | US | claimed |
| EP-4211130-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | COMPASS Pathfinder Limited (GB) | 2023-07-19 | — | — | EP | claimed |
| US-20220305461-A1 | MEDIA FOR SEPARATING SMALL MOLECULES FROM BIOMACROMOLECULES IN AQUEOUS MIXTURES | KREBS JOSEPH F (US) | 2022-09-29 | — | — | US | claimed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2022053696-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | COMPASS PATHFINDER LIMITED (GB) | 2022-03-17 | — | — | WO | claimed |
| CN-114053428-A | Nano-carrier for combined treatment of tumor chemotherapy and radiotherapy, preparation method and application | 南京工业大学 | 2022-02-18 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-12427187-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-12391751-B2 | Antibody against advanced glycation end products and use thereof | BLOOM TECHNOLOGY CORPORATION (JP) | 2025-08-19 | — | — | US | disclosed |
| CN-115976028-B | Glycogen disease type Ia therapeutic agent | 第一三共株式会社 | 2025-03-25 | — | — | CN | disclosed |
| CN-112703200-B | Antibodies against saccharification end products and uses thereof | 布鲁姆科技株式会社 | 2025-01-10 | — | — | CN | disclosed |
| US-4352792-A | 3-Alkoxyflavone antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 1982-10-05 | — | — | US | disclosed |
| US-4311698-A | Aminoacid derivatives of cephalosporin compounds | HASKELL THEODORE H | 1982-01-19 | — | — | US | disclosed |
| US-4278681-A | N-/6-//ACYLAMINOACYLAMINO OR AMINOACYLAMINO/PHENYL/-1,2-DIHYDRO-2-OXONICOTINYL/PENICILLINS | WARNER-LAMBERT CO. (US) | 1981-07-14 | — | — | US | disclosed |
| EP-0019081-A1 | Flavone derivatives, their preparation, these novel and known flavones as antiviral agents, and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-11-26 | — | — | EP | disclosed |
| EP-0015773-A2 | N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them | WARNER-LAMBERT COMPANY (US) | 1980-09-17 | — | — | EP | disclosed |
| EP-0015771-A1 | N-(6-((acylaminoacylamino or aminoacylamino)phenyl)-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds, processes for their production, and compositions containing the same | WARNER-LAMBERT COMPANY (US) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391751-B2 | Antibody against advanced glycation end products and use thereof | AGER, GLA, GID4 | FOLH1 154/4885SIRT2 1508/4885SIRT1 1552/4885 |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | FOLH1 4283/4885SIRT2 2667/4885SIRT1 3042/4885 |
| US-12427187-B2 | Glucose-responsive insulin conjugates | GPR119, IRS1, INSR | FOLH1 410/4885SIRT2 3319/4885SIRT1 1862/4885 |
| US-20230322743-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | HTR2A, HTR2C, HTR1D | FOLH1 849/4885SIRT2 936/4885SIRT1 1951/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | FOLH1 3754/4885SIRT2 2590/4885SIRT1 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.